IL228030B - Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia - Google Patents

Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Info

Publication number
IL228030B
IL228030B IL228030A IL22803013A IL228030B IL 228030 B IL228030 B IL 228030B IL 228030 A IL228030 A IL 228030A IL 22803013 A IL22803013 A IL 22803013A IL 228030 B IL228030 B IL 228030B
Authority
IL
Israel
Prior art keywords
gout
compounds
treatment
metabolic disorders
related metabolic
Prior art date
Application number
IL228030A
Other languages
English (en)
Hebrew (he)
Other versions
IL228030A0 (en
Original Assignee
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Biotechnology Inc filed Critical Twi Biotechnology Inc
Publication of IL228030A0 publication Critical patent/IL228030A0/en
Publication of IL228030B publication Critical patent/IL228030B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL228030A 2011-03-11 2013-08-19 Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia IL228030B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451600P 2011-03-11 2011-03-11
PCT/US2012/027993 WO2012125359A1 (en) 2011-03-11 2012-03-07 Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Publications (2)

Publication Number Publication Date
IL228030A0 IL228030A0 (en) 2013-09-30
IL228030B true IL228030B (en) 2018-01-31

Family

ID=46796094

Family Applications (1)

Application Number Title Priority Date Filing Date
IL228030A IL228030B (en) 2011-03-11 2013-08-19 Compounds for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Country Status (16)

Country Link
US (1) US8865689B2 (enExample)
EP (1) EP2683372B1 (enExample)
JP (1) JP6012639B2 (enExample)
KR (1) KR101567885B1 (enExample)
CN (1) CN103429236B (enExample)
AR (1) AR085662A1 (enExample)
AU (1) AU2012229443B2 (enExample)
BR (1) BR112013022332A2 (enExample)
CA (1) CA2829101C (enExample)
ES (1) ES2634562T3 (enExample)
IL (1) IL228030B (enExample)
MX (1) MX350666B (enExample)
PT (1) PT2683372T (enExample)
RU (1) RU2603050C2 (enExample)
TW (1) TWI505827B (enExample)
WO (1) WO2012125359A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101567925B1 (ko) * 2010-04-08 2015-11-10 티더블유아이 바이오테크놀로지 인코포레이티드 당뇨병 보조치료요법으로서 디아세레인을 사용하는 방법
US8865689B2 (en) 2011-03-11 2014-10-21 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN103638020A (zh) * 2013-12-20 2014-03-19 中美华世通生物医药科技(武汉)有限公司 一种治疗痛风的新型药物组合物
CN104491839B (zh) * 2014-11-27 2016-06-22 青岛大学附属医院 丝氨酸蛋白酶抑制剂b3用于治疗痛风性肾病的用途
KR101647348B1 (ko) * 2014-12-30 2016-08-22 충남대학교산학협력단 Shp를 유효성분으로 하는 통풍 예방 및 치료용 조성물
CA2983394A1 (en) * 2015-04-20 2016-10-27 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
AU2016287636B2 (en) * 2015-07-01 2021-09-16 Twi Biotechnology, Inc. Diacerein or rhein topical formulations and uses thereof
JP6887987B2 (ja) * 2015-08-17 2021-06-16 ティダブリューアイ・バイオテクノロジー・インコーポレイテッドTWI Biotechnology, Inc. Ascの発現、nlrp3の発現、及び/又はnlrp3インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ
KR101863604B1 (ko) 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
CN107468955B (zh) * 2017-09-06 2020-07-24 大连医科大学 治疗痛风性关节炎的中药及制备方法
KR102361526B1 (ko) * 2019-07-02 2022-02-11 한국 한의학 연구원 난각막을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
CN113082012A (zh) * 2021-04-26 2021-07-09 北京亿药科技有限公司 紫苏烯在制备预防和/或治疗高尿酸血症药物中的应用
US12269875B2 (en) * 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04009698A (es) 2004-10-04 2006-04-05 Maria Elena Garcia Armenta Formulaciones farmaceuticas solidas conteniendo diacereina y meloxicam.
BRPI0718469A2 (pt) * 2006-10-20 2014-01-21 Regeneron Pharma Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
EP2471515A3 (en) * 2007-09-14 2012-12-26 Wockhardt Limited Rhein or diacerein compositions
EP2300000A1 (en) 2008-07-03 2011-03-30 University of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
TWI473610B (zh) * 2008-10-28 2015-02-21 Twi Biotechnology Inc 包含雙醋瑞因(diacerein)之醫藥組合物
US8865689B2 (en) 2011-03-11 2014-10-21 Twi Biotechnology, Inc. Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia

Also Published As

Publication number Publication date
RU2603050C2 (ru) 2016-11-20
JP6012639B2 (ja) 2016-10-25
BR112013022332A2 (pt) 2017-05-30
RU2013145498A (ru) 2015-04-20
MX2013010384A (es) 2013-10-07
AU2012229443B2 (en) 2017-03-02
IL228030A0 (en) 2013-09-30
KR101567885B1 (ko) 2015-11-10
AU2012229443A1 (en) 2013-09-12
WO2012125359A1 (en) 2012-09-20
TWI505827B (zh) 2015-11-01
EP2683372A1 (en) 2014-01-15
KR20140019795A (ko) 2014-02-17
CA2829101A1 (en) 2012-09-20
EP2683372A4 (en) 2014-08-06
MX350666B (es) 2017-09-12
ES2634562T3 (es) 2017-09-28
JP2014507476A (ja) 2014-03-27
NZ614486A (en) 2014-11-28
CN103429236B (zh) 2016-09-21
AR085662A1 (es) 2013-10-16
TW201249432A (en) 2012-12-16
PT2683372T (pt) 2017-10-25
EP2683372B1 (en) 2017-07-12
CN103429236A (zh) 2013-12-04
US8865689B2 (en) 2014-10-21
US20120232044A1 (en) 2012-09-13
CA2829101C (en) 2019-08-20

Similar Documents

Publication Publication Date Title
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
IL228030A0 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
IL231533B (en) Fusion proteins for treating metabolic disorders
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
SI2707029T1 (sl) Metode zdravljenja ali preprečevanja s holesterolom povezanih motenj
DK2734126T3 (da) Medicinske anordninger med aftagelige drejelige kæber
PL2919796T3 (pl) Zastosowanie bakterii akkermansia w leczeniu zaburzeń metabolicznych
IL231092A0 (en) Treatment of rhinitis
PL2776055T3 (pl) Sposoby leczenia zaburzeń żołądkowo-jelitowych
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
IL231907B (en) Compounds and compositions for treatment of transthyretin-associated amyloidosis
IL227747A0 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
HRP20181980T1 (hr) Ciklezonid za liječenje dišnih puteva kod konja
BR112013015048A2 (pt) composição para o tratamento de distúrbios metabólicos
IL238592B (en) Compounds for treatment of liver diseases
PL2780003T3 (pl) Leczenie niedoczynności kory nadnerczy
ITRM20120405A1 (it) Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
GB201006167D0 (en) Compounds for the treatment of metabolic disorders
BR112014011898A2 (pt) métodos e composições para o tratamento de diabetes e sintomas relacionados
DK2694056T3 (da) Terapeutisk behandling
GB201006166D0 (en) Compounds for the treatment of metabolic disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed